PBYI.US Puma Biotechnology Inc

Healthcare Biotechnology USA Stocks
7.34 USD
Close of Nov 17, 2026
4.80 11.50
Market cap
USD 379M
P/E
16.7x
P/B
2.73x
ROE
9.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PBYI.US undervalued?

Graham number
Price7.34
Graham value5.16
Premium42.3%

PBYI.US trades 42.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Puma Biotechnology Inc fundamental analysis

No fundamental analysis for Puma Biotechnology Inc yet.

Puma Biotechnology Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor …

Full company profile